Psychosis Associated With Alzheimer's Disease FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 2 Psychosis Associated With Alzheimer's Disease drugs. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| karxt (BMS-986510) | BMY | — | — |
| ML-007C-MA | MPLT | — | — |
Upcoming catalysts
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| October 2026Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Psychosis Associated With Alzheimer's Disease | Delayed | ClinicalTrials.gov |
All indications · Approval rates by indication
Questions
What Psychosis Associated With Alzheimer's Disease drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.